Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Speculative Buy and lowers the price target from $18 to $13.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.